MediWound Reports Highlights From The European Burns Association Congress

YAVNE, Israel, Sept. 29, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, reports highlights from the 26 scientific presentations, the symposium and workshop dedicated to the integration of NexoBrid as standard-of-care to treat severe burns at the 16th European Burns Association (EBA) Congress that took place last week in Hannover, Germany with an audience of approximately 900 burn specialists and other health care professionals from 64 participating countries. The abstracts for the presentations can be accessed at http://www.eba2015.de/programme/scientific-programme/.

Key presentations highlighted the clinical merits of NexoBrid including:

• Studies on the successful outcomes using NexoBrid in anatomical areas that currently are challenging to treat such as hands, breast area, scalp, elbows and face
• Studies that looked at the budget impact of using NexoBrid, including significant savings for hospitals using NexoBrid early on, in the treatment protocol
• Reports from burn centers that have introduced NexoBrid for the first time into their practice and have developed useful protocols and tools to optimize its utilization, engagement and empowerment of the entire burn care team
• Studies on the use of NexoBrid in the pediatric subpopulation
• Discussions on how NexoBrid can be used in a mass casualty scenario to help care for the large number of casualties with limited resources
• The role NexoBrid can play in the direct visual assessment of burn depth which is a critical factor in determining subsequent treatment towards wound healing
• Emphasis on the importance of rapidly removing the eschar from the patient and how NexoBrid allows clinicians to do so immediately upon admission without surgical trauma

"The excitement surrounding the bolus of positive data on NexoBrid presented by burn specialists throughout Europe, who have firsthand experience with NexoBrid, was evident in the overwhelming response to our workshop, symposium and exhibit booth at the EBA. Throughout the Congress, our exhibit booth was consistently crowded with clinicians interested in learning more about NexoBrid treatment. Our symposium and workshop were particularly successful as each was significantly oversubscribed. We were delighted with the opportunity to facilitate peer-to-peer discussions that shared best practices between burn teams from different centers and countries. In addition, throughout the conference we were approached by leading burn experts from countries in Latin American and Asia Pacific, including the presidents of the burn societies in Argentina, Brazil, Mexico, and China, all expressing their interest in introducing NexoBrid into their respective countries, which is in line with our strategy to expand the use of NexoBrid into these emerging markets," stated Gal Cohen, President and Chief Executive Officer of MediWound.

NexoBrid represents a new paradigm in burn care management having demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove in a single, four-hour application the dead or the damaged tissue (eschar) earlier than other modalities, without harming viable tissue. In clinical studies NexoBrid has demonstrated a significant reduction in surgical burden with long-term outcomes that are comparable to the current surgical treatment. NexoBrid was granted marketing authorization from the European Medicines Agency and the Israeli Ministry of Health for the removal of eschar in adults with deep partial and full-thickness thermal burns, and has been launched in both territories. MediWound is currently conducting a Phase 3 clinical study with NexoBrid in the U.S. for the removal of eschar in adults with deep-partial and full-thickness thermal burns.

Speaking at a Key Opinion Leader panel discussion, José Ramón Martínez, M.D., chief of the burn center at the University Hospital, La Paz, Madrid, Spain, noted "it was clearly shown that the use of NexoBrid will reduce the number of surgical procedures, will reduce the extent of the donor site because if you graft, you need to take skin from healthy areas and if you've less grafting, you have less donor areas, less new open wounds, which otherwise would cause more suffering to the patient."

"The wealth of positive data in support of NexoBrid underscores the growing interest in and adoption of our novel enzymatic debridement in the treatment of severe burns. The breadth of clinical data presented covered every important area needed to transform NexoBrid from a novel therapy to a new standard-of-care in severe burn treatment. We look forward to the continued adoption of NexoBrid across Europe and to advancing our U.S. Phase 3 clinical trial in order to have this potentially life-saving treatment available to benefit burn victims in the U.S.," added Mr. Cohen.

About the European Burns Association

The European Burns Association (EBA) is a non-profit organization dedicated to the promotion of burn prevention, the study of the prevention of burn injury and all aspects of burn treatment. It also serves as a resource to facilitate communication and collaboration between burn care specialists. An exchange of information between the various burn centers in Europe will help the EBA to promote its goals. The purpose of the Congress is to bring medical specialists, researchers, paramedics, nurses and other workers in contact to discuss aspects of burn treatment and research.

About MediWound Ltd.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency and from the Israeli Ministry of Health for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials and the regulatory authorizations. Forward-looking statements are based on MediWound's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the FDA or the EMA regulatory approval process, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contacts:	Anne Marie Fields
Sharon Malka	Senior Vice President
Chief Financial & Operation Officer	LHA
MediWound Ltd.	212-838-3777
ir@mediwound.co.il	afields@lhai.com

Help employers find you! Check out all the jobs and post your resume.